Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

AIMS/HYPOTHESIS: Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval. Individual trials have assessed the clinical profile of tirzepatide vs different comparators. We conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Karagiannis, Thomas, Avgerinos, Ioannis, Liakos, Aris, Del Prato, Stefano, Matthews, David R., Tsapas, Apostolos, Bekiari, Eleni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112245/
https://www.ncbi.nlm.nih.gov/pubmed/35579691
http://dx.doi.org/10.1007/s00125-022-05715-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112245/
https://www.ncbi.nlm.nih.gov/pubmed/35579691
http://dx.doi.org/10.1007/s00125-022-05715-4

Ejemplares similares